Stroke & TIA Pharmacotherapy
Core concept: Stroke pharmacotherapy is time dependent and type dependent. Acute ischemic stroke, TIA, intracerebral hemorrhage, and subarachnoid hemorrhage require fundamentally different medication strategies.
Key clinical distinction: Reperfusion therapy is appropriate only after hemorrhage has been excluded and eligibility has been assessed. Antiplatelet or anticoagulant secondary prevention depends on the stroke mechanism, not simply the presence of a prior stroke.
Prescribing priority: Establish last-known-well time, obtain urgent brain imaging, assess blood pressure and glucose, and promptly screen for anticoagulant exposure and reperfusion contraindications. Do not delay otherwise eligible reperfusion while completing the full etiologic stroke workup; determine stroke mechanism to guide subsequent antithrombotic therapy and secondary prevention.
First Decision: Is This Ischemic or Hemorrhagic?
Noncontrast brain imaging is essential before reperfusion or routine antithrombotic treatment because the same therapy that benefits ischemic stroke can worsen intracranial bleeding. Acute stroke care also requires rapid assessment of airway, glucose, temperature, oxygenation, blood pressure, anticoagulant exposure, and neurologic deficit severity (Winkler, 2026).
Primary Prevention Starts Before the First Neurologic Event
Primary stroke prevention is driven mainly by treatment of modifiable vascular risk: control hypertension, treat dyslipidemia according to ASCVD risk, address diabetes, support smoking cessation and physical activity, and identify atrial fibrillation when anticoagulation is indicated. Routine aspirin is not synonymous with primary stroke prevention; any primary-prevention antiplatelet decision must justify its bleeding risk using the patient’s broader cardiovascular indication and current prevention guidance (Winkler, 2026).
Acute Ischemic Stroke: Reperfusion Before Routine Antithrombotics
For eligible patients with disabling acute ischemic stroke, give IV thrombolysis promptly within 4.5 hours of symptom onset or last-known-well. Do not delay standard-window treatment for advanced multimodal imaging when standard criteria are met. Tenecteplase 0.25 mg/kg IV (maximum 25 mg) or alteplase 0.9 mg/kg IV (maximum 90 mg) are guideline-supported options in this standard window. Selected patients with unknown onset or 4.5–9 hours from onset may qualify for IV thrombolysis when appropriate advanced imaging demonstrates salvageable tissue or qualifying mismatch. This is not a blanket extension of the standard treatment window. Evaluate for thrombectomy independently when large-vessel occlusion is suspected (Prabhakaran et al., 2026; Winkler, 2026).
Therapy | Typical regimen / threshold | High-yield safety point |
|---|---|---|
Alteplase | 0.9 mg/kg IV (maximum 90 mg); 10% as bolus, remainder over 60 minutes | Selected patients within 4.5 hours; major risk is symptomatic intracranial hemorrhage |
Tenecteplase | 0.25 mg/kg IV bolus (maximum 25 mg) for eligible acute ischemic stroke | Single-bolus fibrinolytic; institutional protocol and eligibility criteria still apply |
BP before IV reperfusion | Lower to ≤185/110 mm Hg | Use titratable IV therapy such as labetalol, nicardipine, or clevidipine when needed |
BP during/after reperfusion | Maintain ≤180/105 mm Hg for 24 hours | Avoid excessive BP reduction that could impair cerebral perfusion |
After alteplase or tenecteplase, avoid antiplatelet and anticoagulant therapy for the first 24 hours and obtain follow-up brain imaging before starting them. Minimize unnecessary invasive procedures during this period because bleeding risk is increased (Winkler, 2026).
Blood Pressure Strategy Depends on Reperfusion Eligibility
In acute ischemic stroke, reflexively normalizing an elevated BP can reduce perfusion to ischemic penumbra. If the patient is not receiving IV or endovascular reperfusion, antihypertensive treatment is generally withheld unless BP is severely elevated (approximately >220/120 mm Hg) or another emergency such as aortic dissection, ACS, or acute HF requires treatment. If treatment is needed without reperfusion, a modest reduction of approximately 15% over the first 24 hours is generally appropriate. Avoid rapid normalization (Winkler, 2026). Following successful endovascular thrombectomy, intensive SBP lowering below 140 mm Hg is not recommended as a routine strategy (Prabhakaran et al., 2026).
Antiplatelet Therapy After Ischemic Stroke or TIA
Aspirin is recommended for most acute ischemic strokes once hemorrhage has been excluded and reperfusion-related timing allows it. In patients not treated with fibrinolysis, aspirin is typically started within 24 to 48 hours. For minor noncardioembolic stroke or high-risk TIA, short-course DAPT with aspirin plus clopidogrel started early and continued for 21 days reduces early recurrent stroke risk; prolonged DAPT beyond the short treatment window increases bleeding without added benefit for most patients (Winkler, 2026).
Long-term noncardioembolic secondary prevention generally uses single antiplatelet therapy: aspirin, clopidogrel, or aspirin/extended-release dipyridamole according to tolerance and patient factors. CYP2C19 loss-of-function can reduce clopidogrel activation and may support use of an alternative strategy in selected patients (Winkler, 2026).
Cardioembolic Stroke Requires an Anticoagulation Strategy
Atrial fibrillation changes secondary prevention from antiplatelet-centered therapy to oral anticoagulation unless contraindicated. The timing of anticoagulation after an acute ischemic stroke depends on infarct size, hemorrhagic transformation risk, neurologic severity, and imaging. Successful rate or rhythm control does not remove the need for anticoagulation when thromboembolic risk remains high (Winkler, 2026).
Do Not Use Routine Full-Dose Heparin for Acute Ischemic Stroke
Urgent full-dose UFH, LMWH, or heparinoids are not recommended as routine treatment for acute ischemic stroke because they do not improve neurologic outcomes and increase intracranial bleeding and hemorrhagic-transformation risk. Low-dose prophylactic anticoagulation is a separate issue for immobile patients and is delayed until at least 24 hours after fibrinolytic therapy (Winkler, 2026).
Hemorrhagic Stroke: Stop the Bleeding Strategy
Intracerebral and subarachnoid hemorrhage require neurocritical care, controlled BP management, treatment of increased intracranial pressure and seizures when indicated, and immediate review of antithrombotic exposure. Anticoagulant-associated ICH requires urgent reversal according to the specific drug, time of last dose, renal function, and available reversal strategy. Platelet and fibrinolytic decisions differ from ischemic stroke; do not continue an ischemic-stroke algorithm once hemorrhage is identified (Winkler, 2026).
Aneurysmal Subarachnoid Hemorrhage: Nimodipine Prevents Delayed Ischemia
Aneurysmal subarachnoid hemorrhage has a distinct pharmacologic complication: delayed cerebral ischemia. Oral nimodipine should be started promptly after the hemorrhage and, in the 2026 Pharmacotherapy chapter, is given as 60 mg every 4 hours for 21 days. Monitor blood pressure, neurologic status, and fluid balance; hypotension can limit therapy and requires specialist management rather than abandoning the prevention goal without reassessment (Winkler, 2026).
Secondary Prevention Is Mechanism Based
- Noncardioembolic stroke/TIA: antiplatelet therapy rather than routine oral anticoagulation.
- Atrial fibrillation or another cardioembolic source: oral anticoagulation when appropriate.
- Hypertension: aggressive long-term BP control is one of the most important recurrent-stroke interventions.
- Atherosclerotic disease: high-intensity statin therapy and LDL-C goal-directed treatment.
- Smoking, diabetes, sleep apnea, obesity, physical inactivity, and medication adherence should be treated as stroke pharmacotherapy modifiers, not separate topics.
High-Yield Distinctions
- Never give fibrinolytic therapy before intracranial hemorrhage has been excluded.
- For reperfusion candidates, BP must be ≤185/110 mm Hg before treatment and maintained ≤180/105 mm Hg afterward. Standard IV thrombolysis is within 4.5 hours; selected extended-window cases require advanced imaging and stroke-team eligibility review.
- Do not start aspirin, other antiplatelets, or anticoagulants during the first 24 hours after IV fibrinolysis.
- Minor noncardioembolic stroke or high-risk TIA can benefit from short-course aspirin plus clopidogrel, but prolonged DAPT increases bleeding.
- Routine urgent full-dose heparin does not improve acute ischemic stroke outcomes.
- Secondary prevention must match the mechanism: antiplatelet for noncardioembolic disease, anticoagulation for AF/cardioembolism.
Related YourDNP Resources
- Antithrombotic Pharmacology Foundations
- Hypertension Pharmacotherapy
- Dyslipidemia & Hypertriglyceridemia Pharmacotherapy
- Arrhythmia Pharmacology Essentials
- Acute Kidney Injury
Content last reviewed:
References
Prabhakaran, S., Gonzalez, N. R., Zachrison, K. S., Adeoye, O., Alexandrov, A. W., Ansari, S. A., Chapman, S., Czap, A. L., Dumitrascu, O. M., Ishida, K., Jadhav, A. P., Johnson, B., Johnston, K. C., Khatri, P., Kimberly, W. T., Lee, V. H., Leslie-Mazwi, T. M., Mac Grory, B., Madsen, T. E., . . . Yaghi, S. (2026). 2026 guideline for the early management of patients with acute ischemic stroke: A guideline from the American Heart Association/American Stroke Association. Stroke, 57(8), e316–e436. https://doi.org/10.1161/STR.0000000000000513
Winkler, S. R. (2026). Stroke. In M. A. Chisholm-Burns, J. M. Kolesar, P. M. Malone, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 448-477). McGraw Hill.